Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Oct 12, 2023
Product Development
MC2's Hsp90 inhibitor shows signs of efficacy in hidradenitis suppurativa
Readout sets up ‘first-in-class’ therapy for Phase IIb study in increasingly competitive inflammatory disease
BioCentury | Feb 2, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Aug 27, 2021
Distillery Therapeutics
Super enhancer profiling identifies targets for esophageal carcinoma
BioCentury | Aug 18, 2021
Emerging Company Profile
Ranok: a chaperone-based approach to targeted degradation
Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
BioCentury | Feb 24, 2021
Product Development
Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx
bluebird revealed late Wednesday in its 4Q20 earnings that FDA placed a clinical hold on its trials of LentiGlobin due to suspected unexpected serious adverse reactions in the Phase I/II HGB-206
BioCentury | Nov 25, 2020
Product Development
Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline
At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and
BioCentury | Aug 8, 2020
Translation in Brief
Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more
BioCentury’s roundup of preclinical news
BioCentury | Nov 21, 2019
Tools & Techniques
Measuring real-time PK/PD by monitoring aberrant chaperone activity
Measuring PK/PD in real time by selectively targeting protein networks
Items per page:
1 - 10 of 307